Rare disease drug development requires a fundamentally different approach than traditional clinical programs.

Brain tumours remain one of the most formidable challenges in medical science due to their complex biology, high morbidity, and limited treatment options.

Monoclonal antibodies (mAbs) have revolutionized the landscape of neurodegenerative disease research…

The field of CGT is revolutionizing modern medicine, offering potential curative treatments for diseases previously considered untreatable…

Explore best practices for implementing ICH E8 (R1) principles and achieving greater compliance, quality, and patient-centricity in clinical trials.

Since ICH-GCP E6 R2 made Risk-Based Quality Management (RBQM) ‘official’ back in 2017, we’ve seen an increased uptake…

Regulatory documents submitted to health authorities are business critical.